This past fall, I participated in a series of discussions hosted by the American Journal of Managed Care about health reform and the changing health insurance and delivery landscape. The video below is one exchange from the series, focused on medical management of pricey drugs. One thing I say:
You can’t just grant market exclusivity and say, “The price is whatever you guys want to charge.” That’s just not going to fly anymore.
I was joined by
- Leah Binder, President and CEO of The Leapfrog Group
- Margaret O’Kane, President of the National Committee for Quality Assurance
- Matt Salo, Executive Director of the National Association of Medicaid Directors
- Dennis Scanlon (moderator), Professor of Health Policy and Administration and Director of the Center for Healthcare and Policy Research, College of Health and Human Development, The Pennsylvania State University
I’ll post other videos from the discussion series, but if you can’t wait, you’ll find more here.
